Mount Sinai Tisch Cancer Center

The Mount Sinai Tisch Cancer Center is a vital component of the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, which encompasses seven member hospital campuses across the New York City metropolitan area. Established through the generosity of James and Merryl Tisch, the Mount Sinai Tisch Cancer Center was built upon Mount Sinai’s history of distinguished achievements in cancer research and treatment.

The Mount Sinai Tisch Cancer Center’s mission is to accelerate the prevention and treatment of cancer, improving the lives of cancer patients and their families in our community. 
 

Research at the Tisch Cancer Institute

To accomplish this mission, the Mount Sinai Tisch Cancer Center has four research programs:

1. Cancer Immunology: Identifying the mechanisms underlying the suppression of antitumor immunity in order to inform development of effective immunotherapies
2. Cancer Mechanisms: Understanding cancer cell development and proliferation, and identifying therapeutic approaches that target cancer cell vulnerabilities
3. Cancer Prevention and Control: Reducing the burden of cancer incidence, mortality, and risk factors
4. Cancer Clinical Investigation: Developing new treatment approaches for cancer by translating discoveries into therapeutic trials

The Mount Sinai Tisch Cancer Center supports seven shared resources to facilitate research: Bioinformatics for Next Generation Sequencing; Biorepository and Pathology; Biostatistics; Cancer Genomics Technologies; Flow Cytometry; Human Immune Monitoring Center; and Microscopy and Advanced Bioimaging. It also supports a robust infrastructure for cancer clinical trials including an Early Phase Trial Unit. 

Select Scientific Initiatives at the Tisch Cancer Institute

The Mount Sinai Tisch Cancer Center serves patients in the New York City metropolitan area. Its cancer research programs are focused on the needs of its population, which includes its priority cancers; liver, prostate, breast, colorectal, lung, and multiple myeloma.

Some of the Mount Sinai Tisch Cancer Center’s accomplishments include:

• Developing new cancer vaccines and supporting new pharmacological strategies that rely on research-informed insights into the immune system
• Developing small molecule tool compounds that target cancer drivers and inhibit cancer growth
• Conducting studies on tumor progression that have identified novel mechanisms of tumor metastasis
• Identifying increased environmental exposures for cancers diagnosed among World Trade Center first responders
• Conducting lung cancer screening research and initiatives, which led to new guidelines for lung cancer screening
• Collaborating with other cancer centers to conduct clinical trials that led to the FDA approval of eleven different drug combinations and indications for treatment of multiple myeloma

* Information on this cancer center profile was provided by the Mount Sinai Tisch Cancer Center.